MISONIX INCORPORATEDNASDAQ- MSON.pptVIP

Why Misonix? Would you want to invest in a Company using unique ultrasound technology in these markets? Prostate Cancer Breast Cancer Kidney/Liver Cancers Liposuction Neurosurgery Lithotripsy The Misonix Story Management at Misonix has embarked on a transition strategy that today has positioned the Company for years of growth. This plan includes: Major medical device company Leveraging decades of ultrasound research and existing businesses Allocating assets to build intellectual property portfolio Assembling a diversified line of medical devices with the potential for high growth and margins Developing efficient manufacturing processes and distribution capabilities Track Record of Execution – 5 Years of Progress Track Record of Execution – 5 Years of Progress Allocating Assets – Opportunistic Acquisitions* Expanding product line, manufacturing and servicing capabilities, tactical benefits and technological prowess 1999 – MSON contractual relationship and investment 18% fully diluted equity position in Focus Surgery, developer of HIFU technology Right to produce their products for global distribution (manufacturing margin) Right to sell the Sonablate 500? for prostate cancer in Europe (manufacturing and distribution margins) 100% rights to worldwide license to market and sell HIFU treatments in Kidney, Liver and Breast (manufacturing and distribution margins) The Sonablate 500? Expanding Use of Ultrasound Technology… Investments in high growth medical areas funded from cash flow of medical device products in addition to laboratory and scientific products Make investments consistent with company’s core competency Manufacturing exclusivity plus the rights to other products in exchange for investment Generate marketing/manufacturing efficiencies and revenue growth Apply RD to develop products for other medical device companies and for ourselves Investments in RD Pave Way for Growth Assuming clinical successes, regulatory approval and commercial production Dist